The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are pleased to contribute this statement to the 70th WHO Regional Committee meeting for Europe. EFPIA and IFPMA represent Europe’s and the world’s leading research-based biopharmaceutical companies, as well as national and regional industry associations, respectively....
Read moreWith more than 20 IFPMA member companies, Access Accelerated is the largest collective industry effort to address inequities in non-communicable disease care. Access Accelerated recently launched its Year 3 report, chronicling the initiative’s collective efforts in 2019 to advance access to NCD prevention, treatment and care in low- and middle-income countries. To mark this occasion...
Read moreInterview – BBC World News – COVID-19 vaccine manufacturers want to reassure the public and send a message to regulators 10 September 2020 – By Thomas B. Cueni Thomas Cueni, IFPMA Director General, spoke to BBC World New programme Outside Source, on 8 September 2020, about the need for rigorous regulatory standards for approval of...
Read moreWe all want a coronavirus vaccine. But no matter how urgently action is needed, it is imperative that the highest standards of quality, safety and efficacy are upheld. […] We must prioritise thorough validation of the results of pre-clinical and clinical trials by independent expert bodies. There is no place for political favour or national...
Read moreRead more
Over the last decade the Asia-Pacific has seen an unprecedented shift in the adoption and implementation of high-standard ethical business conduct across its healthcare enterprises, including in the biopharmaceutical sector. This positive uptake of integrity had positioned the region to better prepare for, and now to hope to recover from, the current pandemic.
Read moreThis oped was first published on Pharma Focus Asia on 2 September 2020. Reinforcing business integrity There is great hope placed in science and in the biopharmaceutical’s industry efforts to find a solution that allows the world to “return to normal”. As the biopharmaceutical industry is at the heart of developing tests, treatments and vaccines and...
Read moreIFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D.
Read moreGeneva, 3 September 2020 – Seven months into the pandemic, the innovative biopharmaceutical industry continues to step up work on researching and testing therapeutics that could lower mortality rates or lessen the severity of COVID-19. Over recent months, the results of rigorous clinical trials of repurposed medicines to achieve quick wins have been mixed, while...
Read moreGeneva, 28 August 2020 – In the face of an unprecedented public health and economic crisis, the world’s leading innovative vaccine companies are working in partnership with international organizations, governments, academia and many others across the world in answering the call to develop novel vaccines against SARS-CoV-2. Our goal is to provide vaccines to people once...
Read more